SIGN UP

Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)

February 5, 2024 05:28 PM EST

Novartis to buy MorphoSys for $2.9B after 20 years of creating antibodies with the German biotech

Kyle LaHucik

Senior Reporter

Novartis inked a deal to buy MorphoSys for $2.9 billion, in a move that gives the Swiss Big Pharma a cancer drug on the verge …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

sponsored

Are programs with compounded GLP-1s safe for your population?